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Overview 
The project has been conducted at the Centre for age-related medicine (Regionalt 
kompetansesenter for eldremedisin og samhandling, SESAM) at the Stavanger 
University hospital (SUS) under the supervision given by Prof. Dag Aarsland 
MD PhD, who is research director of SESAM, professor of clinical dementia 
research at Alzheimer’s Disease Research Centre, NVS, Karolinska Institutet, 
and principal investigator of the DemWest study group.  
Alexander Lebedev MD is a medical doctor (specialized in psychiatry), with 
experience in multimodal neuroimaging (PET, fMRI, anatomical MRI, DTI, 
MRS). He participated in imaging studies of depression and anxiety disorders, 
performing analysis of structural and functional imaging data. He is also familiar 
with modern approaches to multivariate data analysis and machine learning 
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techniques. He has been employed as a researcher at SESAM since 2011, and 
was a PhD student in this project.  
Co-supervision was given by:  
Prof. Nils Erik Gilhus MD PhD, who is the head of the Department of Clinical 
Medicine (University of Bergen). He coordinated the project, guiding and 
assessing the study progress, provided overall clinical and academic supervision 
and expertise; 
Eric Westman PhD is an assistant professor at the Department of Neurobiology, 
Care Sciences and Society (Karolinska Institute, Stockholm, Sweden), 
experienced in neuroscience, neuroimaging, advanced approaches to multivariate 
data analysis and machine learning algorithms. He coordinated the imaging part 
of the project, helped with practical support and critical review of the papers; 
Mona Beyer MD PhD is a neuroradiologist at Oslo University Hospital, MRI 
coordinator of the DemWest study and recently worked as a post doc researcher 
with support from the Western Norway regional health authority. She helped 
with practical support, critical review of the papers and provided imaging 
expertise to the project; 
Prof. Arvid Lundervold MD PhD, who is a professor at the Department of 
Biomedicine (University of Bergen) and the head of the Neuroinformatics and 
Image Analysis Laboratory (a part of the Neuroscience Research group). He 
provided expert imaging and numerical input to the project, helped with critical 
review of the manuscripts. 
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Abstract 
 
Background 
Cognitive impairment is a very common problem, especially in older individuals 
with major impact on quality of life, daily functioning, and healthcare. Its 
importance is expected to increase due to the demographic changes. 
Neuroimaging is a rapidly developing field of neuroscience that provides an 
opportunity to study brain mechanisms of cognitive impairment in vivo, which 
may help in the development of new biomarkers and treatment strategies. The 
application of advanced image processing to neuroimaging offers the potential 
for diagnostically relevant analysis techniques, in particular for magnetic 
resonance imaging (MRI). 
  
Aim 
The primary aims of the project were to investigate brain mechanisms of 
cognitive impairment in neurodegenerative diseases using computational 
neuroimaging approaches and to assess their potential applicability in clinical 
practice for detection, prediction and differential diagnosis of cognitive 
impairment in the elderly. 
  
Objectives 
1) To investigate brain changes underlying cognitive impairment in 
neurodegenerative diseases (Alzheimer’s, Lewy body dementia and 
Parkinson’s disease).  
2) To assess the applicability of pattern recognition techniques for: 
a) Differential diagnosis of cognitive impairment  
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b) Prediction of further cognitive deterioration in patients with mild 
cognitive impairment; 
3) To investigate problems associated with implementation of computer-
aided image-based tools for detection, prediction and differential 
diagnosis of cognitive impairment. 
  
Methods 
Five datasets of clinical and imaging data were used, including two large-scale 
databases of Alzheimer’s disease (ADNI and AddNeuroMed).  
In the papers I-II, Alzheimer’s disease was diagnosed according to the NINCDS-
ADRDA criteria. 
Dementia with Lewy bodies (paper I) was diagnosed according to the revised 
consensus criteria (1) 
Image post-processing steps were performed within the surface- (papers I-III) 
and voxel-based (paper IV) frameworks using the Freesurfer and SPM8, 
respectively. Mass-univariate (papers III, IV) and multivariate (papers I, II and 
IV) approaches were used. In the paper IV, an automated quantitative meta-
analysis was also performed using the Neurosynth software. 
  
Results 
Papers I-II  
Optimizing image preprocessing and data analysis pipeline, we found that it is 
possible to develop a computer-aided tool for detection (Sensitivity/Specificity = 
88.6%/92.0%), prediction (Sensitivity/Specificity = 83.3%/81.3%) and 
differential diagnosis (AD/DLB overall classification accuracy = 83.9%) of 
degenerative diseases with good between-cohort robustness if imaging and 
clinical protocols are carefully aligned. For the morphometric data, the use of 
disease-specific brain parcellation schemes resulted in equivalent performance 
 12 
compared to normalized raw high-dimensional input, but required substantially 
lesser tuning time and computation/memory resources. Better accuracy of the 
models can be achieved by adding more biomarkers (e.g., ApoE genotype), 
demographics, and improved disease verification strategies (e.g., post-mortem 
diagnosis) for the data used as a training material for the classifiers.  
The next two papers were focused on neural correlates of cognitive impairment 
in PD that had to be investigated prior considering them within the framework of 
computer-aided diagnosis. 
Papers III-IV 
We found that Parkinson’s-related cognitive impairment affecting multiple 
domains is associated with temporo-parietal and superior frontal thinning. On a 
large-scale network level, better executive performance in PD is associated with 
increased dorsal fronto-parietal cortical processing and inhibited subcortical and 
primary sensory involvement when the subject is at resting state. This pattern is 
positively influenced by the relative preservation of nigrostriatal dopaminergic 
function. The pattern associated with better memory performance favors 
prefronto-limbic processing, and does not reveal associations with presynaptic 
striatal dopamine function.  
 
Conclusions 
Cognitive impairment in the elderly has different brain profiles depending on the 
predominant neurodegenerative pathology and cognitive functions affected. With 
the use of automated computer-aided tools and advanced image processing 
techniques, Alzheimer’s disease can be robustly identified, predicted two years 
before the actual dementia onset and differentiated from dementia with Lewy 
bodies. After certain modifications and adaptations for clinicians, the models can 
be successfully incorporated into medical decision-support systems and be 
evaluated in subsequent diagnostic clinical trials. 
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The identified brain structural and functional profile associated with Parkinson’s-
related cognitive impairment is also robust and, holding strong diagnostic 
potential, must be detectable using computer-aided systems of similar design, the 
development of which is the matter of our future research. The development and 
future elaboration of clinically realistic computer-aided systems for the diagnosis 
of neurodegenerative diseases is an important topic for future research. 
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1. Introduction 
Preliminary remarks 
Oxford dictionary defines cognition as “the mental action or process of acquiring 
knowledge and understanding through thought, experience, and the senses” (2). 
Pain, tactile, visual and auditory experiences, joy, fear, beliefs, desires, attitudes, 
intentions – all kinds of mental phenomena pass through the “prism” of 
cognition. Individual differences in cognitive functions define us as individuals 
to a very large extent: how smart we are, how good we are at foreseeing our 
future, life planning, decision making, learning, emotion control, even the clarity 
of the text that you are currently reading is largely influenced by the author’s and 
reader’s cognitive functions. 
An enigmatic boost of monkeys’ cognitive abilities, so-called “cognitive 
revolution” that happened about 70,000 years ago, have made us humans and 
determined appearance and future development of science, art and other 
inalienable aspects of our modern life (3).  
Today we live in the “golden age” for cognitive neuroscience. We have already 
started recovering lost cognitive abilities with a help of pharmacology, advanced 
brain surgery, implanting, gene therapy and engineering. Apart from this, recent 
advances in computer science made it possible to run simulations of certain 
aspects of cognition and even to share some of our cognitive abilities with 
computers that are rapidly becoming better and better at tasks previously thought 
as unfeasible for the machines, such as playing chess, natural language 
processing, voice and image recognition. 
The main inspiration for this thesis is the hope that the fusion between 
neuroscience, computer science and humanism will ultimately help us to 
overcome a devastating burden of neurodegenerative diseases and improve 
quality of life in the elderly. 
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Cognitive impairment in the elderly and its impact on society 
Multiple cognitive impairments that sufficiently affect activities of daily living 
manifest as dementia syndrome, which is the end-stage of many 
neurodegenerative diseases. Most frequently impaired domains with major 
impact are memory, executive, visuo-spatial functions, language and praxis.  
The diseases that cause dementia tend to have a progressive course. The most 
frequent causes of neurodegenerative dementia – Alzheimer's and Lewy Body 
diseases are often co-morbid and have an age-related incidence, which, in turn, 
explains the rapid growth of its prevalence, associated with the population ageing 
(4). Thus, only in Norway, about 60000 – 70000 people suffer from dementia 
and this number is expected to double by 2050 (5). 
It is not only patients and their caregivers who are affected by this devastating 
condition, but also the world society and global healthcare. Thus, financial 
burden of dementia is very high, equivalent to the one of heart disease and cancer 
(6), and set to grow exponentially over the next decades. In 2010, its total 
worldwide costs were estimated at 604 billion US dollars, and are expected to 
increase by 85 % by 2030 (7). This problem is even more serious, given that 
doctors specializing in age-related medicine are already in short supply, and the 
demand for them is becoming higher every year (8). 
Several strategies to overcome these issues can be undertaken. Developing novel 
treatments to prevent or modify neurodegenerative diseases is probably the most 
crucial one. Thus, only for Alzheimer’s disease, there are numerous ongoing 
clinical trials, the results of which will hopefully provide an opportunity to slow 
down or stop the disease progression. In this context, early detection and 
prediction of dementia is very important to select those who would have highest 
benefits from these trials. Importantly, one of the recent reports of Alzheimer’s 
Disease International (ADI, the international federation of Alzheimer 
associations around the world) was specifically focused on the benefits of early 
diagnosis and interventions in AD (9). This report also suggests that early 
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diagnosis of AD reduces costs itself by improving institutionalization strategies 
and enhancing quality of life of patients and their caregivers.  
All of the above, therefore, presents a need for the improved detection of 
cognitive impairment in the elderly at early stages, and neuroimaging is one of 
the most promising sources for this. 
 
Brain Imaging 
Brain imaging can be defined as a set of invasive and non-invasive techniques to 
image the structure, function or biochemistry of the brain. Plenty of methods are 
available in this field today such as magnetic resonance imaging, single-photon 
emission computed tomography (SPECT), positron emission tomography (PET) 
with different ligands including pathology-specific ones like, for example, 
Pittsburgh Compound B (PIB) and others (10). 
Magnetic resonance imaging (MRI) is a very informative and non-invasive 
method. After its invention by Felix Bloch and Edward Purcell followed by 
Nobel Prize in 1952 it took two decades before clinical implementation of this 
technique became possible (11). 
Today MRI is widely used for the diagnosis of dementia (10, 12), and many 
specialized MRI protocols and approaches to the data analysis have been 
developed, providing extremely wide spectrum of structural and functional 
information (13).  
Although MRI is now implemented in the diagnostic criteria for Alzheimer’s 
disease (14), it does not seem to reliably differentiate between all dementia types, 
at least with a visual assessment of anatomical MRI scans (15). Meanwhile, it is 
important to have a reliable differential diagnosis particularly between 
neurodegenerative diseases such Alzheimer’s and dementia with Lewy bodies. 
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Brain imaging of cognitive impairment in Alzheimer’s disease and dementia 
with Lewy bodies 
A diagnostic hallmark of AD, medial temporal lobe (MTL) atrophy, has been 
shown to be closely associated with episodic memory impairment, which, in turn, 
is one of the main clinical features of the disease (16, 17) (18).  
Meanwhile, emerging evidence suggests that AD may be a heterogeneous disease 
with several concomitant pathogeneses (19-21). Thus, neuropathological and 
neuroimaging studies revealed several manifestations of AD (typical, 
hippocampal-sparing, and limbic-predominant forms) that differ in patterns of 
neurofibrillary tangles distribution, brain atrophy, gender proportion, 
apolipoprotein E (ApoE) and microtubule-associated protein tau (MAPT) allele 
frequencies (20, 21), as well as several clinical manifestations that differ in the 
age of onset and cognitive functions affected (19, 22-24) (19, 25). A recent large-
sample study performed visual assessment of atrophy patterns associated with 
cognitive dysfunction in multiple domains in AD. The authors found that MTL 
atrophy was associated with worse memory, language and attention performance, 
whereas “posterior atrophy” (posterior cingulate, parieto-occipital regions, 
precuneus) was associated with worse performance on visuospatial and executive 
functioning (18).  
Typical brain changes associated with progression of Alzheimer’s disease follow 
a consistent pattern affecting entorhinal cortex on early stages, then hippocampal 
Cornu Ammonis (CA) subfields, amygdala, and finally neocortical areas (26). 
This progressive atrophy can be successfully visualized in vivo with the help of 
structural MRI. Visual assessment of medial temporal lobe (MTL) atrophy on 
MRI scans has a substantial clinical value in detection of AD with overall 
accuracy higher than 80% (27-29). Its ability to predict MCI-to-AD progression, 
however, is varying around 60-65% (30, 31). All of the above made MTL 
atrophy become one of the biomarkers in proposed Dubois’ criteria for 
prodromal AD (14). 
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There are also some preliminary evidences suggesting that MRI may help to 
differentiate AD from the second most common neurodegenerative disease in the 
elderly, DLB (29) (32). However, these results are limited due to different 
methodological frameworks and small sample sizes. 
Functional MRI (fMRI) is a noninvasive technique that allows to indirectly 
measure brain activity, assessing changes in so-called BOLD (blood oxygenation 
level-dependent) signal (33). Functional MRI can be implemented within the 
context of cognitive tasks (e.g., comparing “baseline” and “active” conditions) or 
when the subject is at resting state without any particular task (34). Both task-
related and resting fMRI (rs-fMRI) techniques are non-invasive, safe and have 
the potential to detect early brain functional abnormalities associated with 
cognitive impairment in the elderly, and to monitor their progression and 
therapeutic response.  It has recently been shown that rs-fMRI may assist in 
differentiation between AD and DLB (35). The main limitations of BOLD fMRI, 
however, are substantial difficulties of signal quantification (the method usually 
assesses either contrast or temporal correlations of signal changes), low signal-
to-noise ratio and high susceptibility to artifacts, MRI protocol differences and 
field strength. All of the above hampers consideration of BOLD fMRI as an 
imaging biomarker. On the other hand novel functional MRI techniques, such as 
arterial spin labeling, measuring brain perfusion are quantifiable and hold 
stronger potential to be used in clinical practice. 
MRI can provide relevant support in the diagnosis of AD, detecting progressive 
atrophy, which starts from the entorhinal cortex and gradually spreads 
throughout the brain (12), but, as mentioned above, is currently less useful for 
differentiation between AD and other neurodegenerative diseases.  
Although Alzheimer’s and Lewy body pathologies are often present together in 
autopsy materials, there are strong evidences suggesting that corresponding 
clinical manifestations, depending on predominant pathology, demonstrate 
substantially different morphological profiles, primarily, with greater 
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involvement of hippocampal formation and related neocortical areas in AD; this 
may explain more severely impaired memory function in AD as compared to 
DLB (36-38). On the other hand, the neuropathological basis of DLB primarily 
includes subcortical, frontal, temporal, and parietal lobes, which in turn may 
explain the predominance of visuospatial, attentional, and executive function 
impairment in these patients (39-42). Inconsistent findings have been reported 
regarding the involvement of cingulate and frontal cortex in LBD compared to 
AD. Both post mortem (43), as well as studies using imaging techniques such as 
SPECT-perfusion (44), PIB-PET (45), diffusion-tensor imaging (46, 47), have 
reported cingulate involvement in Lewy Body dementia. There are several 
reports on frontal lobe atrophy in DLB (48-50). However, recent studies found 
orbitofrontal (51) and, on the large sample, even the whole (52) cortex to be 
preserved in DLB compared to AD. In addition, although there are observations 
from functional studies showing metabolic (53) and perfusion (54) reductions in 
occipital lobes in DLB compared to AD, no significant volumetric differences in 
this region were found (55, 56).  
These findings are highly important for uncovering brain mechanisms and for 
understanding the pathomorphological and pathophysiological differences in 
these conditions.  
However, whether MRI can assist in the reliable differentiation between AD and 
LBD is not yet clarified, mainly because most studies do not report sensitivity 
and specificity, providing only group differences.  
 
Brain imaging of cognitive impairment in Parkinson’s disease    
Cognitive impairment is a very important and common non-motor feature of 
Parkinson’s disease (PD) with a major impact on patients’ quality of life and 
healthcare costs (57-59). Approximately one-fifth of newly diagnosed PD 
patients fulfill clinical criteria for mild cognitive impairment (PD-MCI) (60). 
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About one-sixth develop dementia after 5 years (61), and more than 80% of PD 
patients will eventually develop it as the disease progresses (62). 
Although the exact role and mechanisms of the dopaminergic system in 
cognition are still a matter of debate, there is no doubt that its preservation is 
crucial for cognitive functioning of PD patients. There is strong evidence 
suggesting that the impairment of at least 3 major dopaminergic pathways 
(nigrostriatal, mesocortical, mesolimbic) originating in the brainstem play a very 
important role in cognitive dysfunction associated with PD (63).  
Previous neuroimaging studies assessing brain networks in vivo have shown 
impairment of the dopaminergic pathways and related neural circuits in PD. 
Numerous studies on cognitive dysfunction associated with PD have revealed 
structural and functional abnormalities within the cortico-strio-thalamo-cortical  
circuits, known to be largely modulated by the dopaminergic system (64, 65). 
Decreased 6-[18F]-fluorodopa (18F-DOPA) uptake in the anterior cingulate cortex, 
ventral striatum and right caudate nucleus has been found in PD patients with 
dementia (PDD) compared to PD (66). Studies employing Single Photon 
Emission Computed Tomography (SPECT) with the dopamine transporter-
binding ligands (DaTSCAN) also suggest more severe striatal presynaptic 
dopaminergic deficiency in PDD compared to PD patients, especially in the 
caudate nuclei (67). In addition, there is also evidence suggesting an association 
between striatal 18F-DOPA uptake and executive performance in PD patients (68-
70).  
Several 18F-fludeoxyglucose Positron Emission Tomography (FDG-PET) studies 
analyzing brain networks in PD have identified partially overlapping patterns of 
brain metabolic changes associated with cognitive impairment in multiple 
domains, suggesting that the PD-related profile of cognitive impairment is 
associated with reduced glucose metabolism mainly in prefrontal, parietal, 
hippocampal and striatal regions (71-74).  
H215O-PET studies have shown an impaired basal ganglia and dorsolateral 
prefrontal response during executive task performance in PD (75-77). 
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Functional MRI studies have also revealed abnormalities within the frontal-
subcortical circuits in patients with PD. For instance, an abnormal fronto-striatal 
response during executive task performance has been found in cognitively 
impaired PD patients compared to non-impaired ones (78) (79). Another fMRI 
study assessing working memory and motor functions in ON and OFF 
dopaminergic medication states in PD patients (80) found increased prefrontal 
and parietal activations during the working memory task performance in the OFF 
state, which were positively correlated with errors during the task. Studies 
focusing on set-shifting paradigms have found a PD-associated pattern of 
prefrontal and parietal response characterized by either reduced or increased 
activation depending on whether the caudate nucleus was involved in the task 
(81, 82).  
Impaired deactivation of the default mode network during executive task 
performance has been reported in several fMRI studies of PD (83, 84). Resting 
state fMRI studies have reported abnormal cortico-striatal connectivity in PD 
(85-87), while L-DOPA administration has been shown to enhance functional 
connectivity in the frontal areas of the sensorimotor network (88). 
 
Computational Neuroimaging and Computer-Aided Diagnosis 
The era of computing is associated with significant changes in human life, 
uncovering a lot of valuable opportunities in many fields and particularly in 
medicine. Computational neuroimaging is a relatively new field of neuroscience 
and represents one of the most promising areas to provide diagnostically relevant 
analytic framework. Different techniques, methods and image post-processing 
approaches exist in this field (10, 89). Combined with pattern recognition 
techniques, computational approaches to structural MRI have already been 
shown to be effective for detection of AD, frontotemporal dementia (FTD) and 
mild cognitive impairment (MCI) (90-93) and hopefully will provide robust 
differential diagnosis in AD and DLB patients.  
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In this context, computer-aided diagnosis (CAD), defined as a family of 
computational approaches developed to assist doctors in the detection of 
abnormalities, quantification of disease progress and differential diagnosis (94), 
is a very promising subfield with high potential to be implemented in clinical 
practice. Potentially, it is a very cost-effective approach, since after the 
implementation it requires minimum technical staff to be maintained. Among 
other advantages of CAD is its unbiasedness toward human mistakes, global 
access, and possibility to establish a constantly updating large flow of the 
standardized data, which, in turn, may provide a very good research and clinical 
material for further improvements and serve as an additional incentive to 
implement these techniques in practice. Finally, this technology can be easily 
incorporated into clinical decision-support systems. However, it has its 
drawbacks too. One of the most critical issues pertains to the fact that use of 
these techniques implies a standardized process of data acquisition, which in turn 
requires employment of imaging protocol harmonization and preferably unified 
diagnostic workflows. The use of this technology by a clinician, at least at its 
first stages of implementation, may be associated with some technical difficulties 
(e.g., establishing data transfer, sending queries) and certain amount of technical 
training is therefore required. Lastly, its incentives and organizational 
governance are still a matter of research. It is worth noting though, that these 
issues pertain to modern healthcare in general. Thus, recent United States 
experience in rapid adoption of IT innovations, such as electronic health records 
(EHRs), in response to governmental incentive programs highlighted its 
problems such as a mismatch between EHR software and clinical workflow 
standards, which together with inadequate training and poor preparation of 
medical staff may lead to dissatisfaction and decreased productivity (95-97). So, 
the use of clinical and technical standards together with adequate personnel 
training is indeed a backbone of a successful adoption of any IT innovation, 
including CAD. Among the fields providing material for CAD in 
neurodegenerative diseases, brain imaging stands out as one of the most 
promising. 
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To summarize, neurodegenerative diseases have a devastating impact on society 
and healthcare, with increasing costs and demand for doctors who specialize in 
age-related medicine. Neuroimaging is an important technique that assists 
doctors in the diagnosis of cognitive impairment in the elderly.  Some of the 
techniques are already being implemented in the diagnostic process. The most 
advanced ones (e.g., PiB PET for AD, DaTSCAN for DLB and PD) are 
expensive, difficult to implement and are not widely available for clinicians. It is 
still not clear whether MRI can help to differentiate between AD and DLB, and 
whether it is possible to develop a cohort-robust automated tool for solving 
diagnostic problems with advanced image processing and data analytical 
techniques. 
Apart from this, brain mechanisms of cognitive deterioration associated with 
neurodegenerative diseases in the elderly are still a matter of debate. 
Meanwhile, computational neuroimaging represents a very promising set of 
techniques to study mechanisms of cognitive impairment and to provide 
clinically relevant and automated diagnostic tools. 
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2. Objectives 
1) To investigate brain changes underlying cognitive impairment in 
neurodegenerative diseases (Alzheimer’s, Lewy body dementia and 
Parkinson’s disease).  
2) To assess the applicability of pattern recognition techniques for: 
a) Differential diagnosis of cognitive impairment  
b) Prediction of further cognitive deterioration in patients with mild 
cognitive impairment; 
3) To investigate problems associated with implementation of computer-
aided image-based tools for detection, prediction and differential 
diagnosis of cognitive impairment. 
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3. Hypotheses 
1. With the help of computational neuroimaging, accurate and cohort-robust 
tools can be developed to assist in the differential diagnosis and early 
detection of cognitive impairment in the elderly; 
2. Cognitive impairment in Parkinson’s disease is associated with structural 
and functional abnormalities within temporo-parietal and prefrontal 
circuits; 
3. Brain dynamics underlying cognitive functioning in PD is influenced by 
nigrostriatal dopamine deficiency. 
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4. Methods 
4.1 Cohorts 
In the present project 5 cohorts were used. Their description is summarized in the 
Table M-1 and in the subsequent paragraphs. 
Table M-1. Characteristics of the cohorts 
!! DemWest! Slo! ADNI! AddNeuroMed! PPMI!
Papers! I! II! III,!IV!
Total!N! 63! 34! !808! 321! 179!!
Diagnoses! AD,!DLB! AD,!DLB,!PDD! AD,!MCI,!HC!
PD6MCI,!PD6
NC,!HC!
Imaging!
Modalities!
MRI,!
DaTSCAN!
MRI,!
DaTSCAN!
MRI!(with!harmonized!
protocol)!!
MRI,!fMRI,!
DaTSCAN!
Cognitive!
tests!
MMSE,!CDR,!CVLT6II,!
VF,!BNT,!BLOT,!BFRT,!
ROCFT,!ST!
MMSE,!CDR,!ADAS,!
ANART,!RAVLT,!SF,!WAIS6
R,!BNT,!TMT,!SDMT!
MoCA,!HVLT6
R,!SF,!BLOT,!
LNST,!SDMT!
Country! Norway! Slovenia! North!America!
Europe!
(Finland,!Poland,Italy,!
Greece,!UK,!France)!
USA,!Europe!
and!Australia!
AD - Alzheimer’s Disease, DLB - Dementia with Lewy bodies, PDD - 
Parkinson’s Disease Dementia, MCI - Mild Cognitive Impairment, PD - 
Parkinson’s Disease, NC - Normal Cognition, HC - Healthy Controls; 
 
ADAS - Alzheimer's Disease Assessment Scale (cognitive subscale), ANART - 
American National Adult Reading Test, BFRT - Benton Facial Recognition Test, 
BLOT - Benton Line Orientation Test, BNT - Boston Naming Test, CDR - 
Clinical Dementia Rating scale, CVLT-II - California Verbal Learning Test (II), 
DS - Digit Span test, HVLT-R - Hopkins Verbal Learning Test (Revised), MMSE 
- Mini Mental State Examination, MoCA - Montreal Cognitive Assessment, 
RAVLT - Rey Auditory Verbal Learning Test, ROCFT- Rey-Osterrieth Complex 
Figure Test, SDMT - Symbol Digit Modalities Test, SF - Semantic Fluency, ST - 
Stroop Test, TMT - Trail Making Test, VF - Verbal Fluency, WAIS-R - Wechsler 
Adult Intelligence Scale (Revised). 
 
 
 
1) DemWest (Paper 1)  
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This cohort is based on a population drawn from the Dementia Study in Western 
Norway - DemWest. In this study, all patients referred to the geriatric psychiatry 
and geriatric medicine clinics in Western Norway during 2005-2007 were 
considered for inclusion. Neurology clinics were asked to refer potential 
candidates to the study. Patients with a new diagnosis of mild dementia, without 
confusion or previous history psychotic disorders were invited. Patients were 
diagnosed as probable AD according to NINCDS-ADRDA (National Institute of 
Neurological and Communicative Diseases and Stroke-Alzheimer’s Disease and 
Related Disorders Association), Parkinson’s disease dementia (98), or DLB (1). 
The exclusion criteria were normal cognition or mild cognitive impairment,  
moderate or severe dementia defined as MMSE < 20, recent major physical 
disease, previous affective or psychotic disorder. After 2007, only DLB and PDD 
patients were included, with MMSE between 16-20. 
Routine physical examination and blood tests were performed for all patients, a 
subgroup underwent lumbar puncture for CSF analyses, and ECG was performed 
if clinically indicated. 
A comprehensive battery of standardized clinical assessment instruments was 
administered at baseline and annually, assessing cognitive, psychiatric, and 
motor functions, including a battery of neuropsychological tests. Details of the 
selection and diagnostic procedures have been reported previously (99). 
The Montgomery-Asberg Depression Rating Scale (MADRS) was administered 
by trained study physicians (geriatric psychiatrists or geriatricians) to evaluate 
depression.  
For most patients with suspected DLB single photon emission computed 
tomography (SPECT) procedures with 123I-FP-CIT compound (DaTSCAN) were 
performed. SPECT images were acquired at three institutions on Siemens 
Symbia and E-Cam dual-head Gamma cameras with similar protocols. 
Transversal images through the basal ganglia were visually analyzed by one 
nuclear medicine specialist blinded to all patient information.  
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MRI Images were collected from three centres with harmonized protocols using 
T1-weighted 3D series. The subjects were scanned on 1.5 Tesla MRI scanners at 
3 different sites: Stavanger, Haugesund (Philips Intera) and Bergen (GE Signa 
Excite).  
Reliability assessment 
In order to check intra- and inter-scanner reliability in the DemWest cohort, we 
performed a validation study using human phantom scanning. For this purpose, 
MRI was performed in three healthy subjects with repeat scanning including 
FLAIR and 3D T1 two times at each center on the same day. The MRI 
procedures included two scanning sessions with a pause in between when the 
subject left the MRI room. Human phantom scanning was completed within 3 
months for all participating centers. 
The analysis included estimation of intra- and inter- scanner reliability 
coefficients (Cronbach’s alpha) for intracranial volume (ICV) and mean cortical 
thickness (MCT) measurements. 
Reliability assessment was performed using the ‘‘ltm’’ (Latent Trait Models) 
package (100) in R programming language (101), which is well established and 
freely available for download (http://www.R-project.org/).  
Estimation of the reliability coefficient (Cronbach’s alpha) showed appropriate 
results: the intra-/inter-scanner reliability coefficients for ICV and MT were 
0.996/0.995 (excellent) and 0.945/0.752 (excellent/acceptable) respectively. This 
allowed us to use the images from all three participating centers. 
The study was approved by Regional Committee for Medical Research Ethics in 
Western Norway, and received financial support from the Western Norway 
regional health authority and the Norwegian Research Council. All patients 
signed informed consent to participate in the study. 
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2) Slovenian AD and DLB cohort (paper I) 
The cohort consisted of dementia patients attending the memory outpatient clinic 
at the Department of neurology (University Medical Centre in Ljubljana). The 
diagnosis of dementia was made according to DSM-IV criteria and the diagnosis 
for AD was based on The National Institute of Neurological and Communicative 
Disorders and Stroke-Alzheimer’s Disease and Related Disorders Association 
(102). DLB was diagnosed according to the revised consensus criteria (1) in the 
DemWest cohort and the 1996-criteria for the Slovenian (Slo) cohort (37). For 
the Slo cohort we merged DLB and PDD patients (103), since these syndromes 
share clinical and pathological features (104). 
Standardized clinical screening assessment instruments were administered in 
both cohorts to assess cognitive, psychiatric, and motor functions. Clinical 
assessment was performed using Mini Mental State Examination (MMSE), 
Unified Parkinson Disease Rating Scale, Clinical Dementia Rating scale, 
Neuropsychiatric Inventory and Beck Depression Inventory, detailed 
neuropsychological test battery (Delis-Kaplan Executive Function System, 
California Verbal Learning Test II, verbal fluency test, Boston Naming Test, The 
Rey-Osterrieth Complex Figure Test, Benton Line Orientation Test, Benton face 
recognition test, Stroop test), tests of autonomic functions and assessment of 
daily activities.  In addition to routine blood tests, laboratory assessment of 
thyroid function, vitamin B12 and folate (the patients with vitamin deficiency 
were excluded) was administered. In both cohorts, visual assessment of MRI 
scans (both T1 and T2-FLAIR) were performed to exclude structural pathologies 
other than AD or DLB that could account for the symptoms. Routine physical 
examination was also performed. 
DaTSCAN images were acquired for all patients on Siemens Symbia T2 dual-
head Gamma camera and were evaluated by two independent raters (the first one 
is a specialist in nuclear medicine and the second one is a neurologist with 
additional knowledge in functional brain imaging). They were blinded for the 
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clinical information. Normal/abnormal tracer uptake patterns were analyzed. The 
results were similar in the DLB and PDD patients. 
The study was approved by the local Regional Committee for Medical Research 
Ethics. All patients provided written consent to participate in the study after the 
study procedures had been explained in detail to the patient and a caregiver. 
3) ADNI (paper II) 
Alzheimer’s Disease Neuroimaging Initiative (ADNI) launched in 2004 and was 
aimed at discovering more sensitive and accurate biomarkers for Alzheimer’s 
disease and its progression at earlier stages.  
To date, ADNI is the largest project of its kind, covering thousands of patients at 
different stages of AD and healthy controls. More than 50 centers participate in 
this initiative, to date. 
In total, 808 subjects aged between 55-90 years were enrolled in the ADNI-1 
cohort used in our project.  
Normal subjects had to have MMSE scores above 24, a CDR of 0, had not to 
have clinical depression, MCI or severe cognitive impairment.  
MCI subjects had to have MMSE scores between 24-30, memory complaints and 
objective memory loss (measured by education adjusted scores on Wechsler 
Memory Scale Logical Memory II), a CDR score of 0.5, absence of significant 
levels of impairment in other cognitive domains, preserved activities of daily 
living, and an absence of dementia. 
Patients with mild AD had MMSE scores between 20-26, CDR of 0.5 or 1.0, and 
met NINCDS/ADRDA criteria for probable AD. 
Neuropsychological battery included Alzheimer's Disease Assessment Scale 
(cognitive subscale) (ADAS-Cog), American National Adult Reading Test 
(ANART), BNT - Boston Naming Test, Digit Span test (DS), Rey Auditory 
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Verbal Learning Test (RAVLT), Semantic Fluency (SF), Trail Making Test 
(TMT), Wechsler Adult Intelligence Scale (Revised) (WAIS-R). For more 
details, please visit http://www.adni-
info.org/Scientists/ADNIStudyProcedures.aspx. 
All subjects had clinical assessments, physical examination and 1.5 T structural 
MRI (acquired with harmonized protocols) at specified intervals for 1-5 years.  
The ADNI project is conducted according to Good Clinical Practice guidelines, 
the Declaration of Helsinki, US 21CFR Part 50 – Protection of Human Subjects, 
and Part 56 – Institutional Review Boards. Written informed consent for the 
study was obtained from all subjects and/or authorized representatives and study 
partners. 
4) AddNeuroMed (paper II) 
The study included six centers at University of Kuopio, Finland; University of 
Perugia, Italy; Aristotle University of Thessaloniki, Greece; King's College 
London, United Kingdom; University of Lodz, Poland; and University of 
Toulouse, France. The Karolinska Institutet (Stockholm, Sweden) was 
established as the center for image repository, quality control, and overall 
coordination site.  
Two hundred and twenty one subjects with AD (n=107), 114 MCI (n=114) and 
100 HCs were included. Informed consent was obtained for all subjects, 
protocols and procedures were approved by the local data acquisition site and the 
data coordination center.  
Imaging and clinical protocols were harmonized with the ADNI study (see 
above). For more details see http://www.innomed-addneuromed.com and (105). 
Exclusion criteria included other neurological or psychiatric disease, significant 
unstable systemic illness or organ failure, and alcohol or substance misuse. 
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The project was approved by local Ethical Committees at all participating 
centers. Written consent to participate was obtained from all patients and/or 
caregivers. 
5) PPMI (papers III-IV) 
Parkinson’s Progression Markers Initiative (PPMI) is a large-scale international 
project aimed at discovering novel biomarkers for Parkinson’s disease and its 
progression. The study launched at 21 clinical sites in the United States, Europe, 
and Australia. For details, please see (106). 
To date, more than 450 patients at different stages of PD and more than 250 
healthy controls are included from more than 30 centers throughout the world. 
Inclusion criteria required that subjects must have at least two of the following 
symptoms: resting tremor, bradykinesia, rigidity or either asymmetric resting 
tremor or asymmetric bradykinesia. In addition, the subjects had to have Hoehn 
and Yahr stage I or II at baseline, and a pathological 123I-FP-CIT SPECT scan. 
Exclusion criteria were atypical PD syndromes due to drugs or metabolic 
disorders, encephalitis, or other degenerative diseases. In addition, it was 
required that the subject was not taking levodopa, DA agonists, MAO-B 
inhibitors, amantadine or other Parkinson’s disease medication; or had taken 
levodopa or dopamine agonists prior to baseline for more than a total of 60 days.  
This cohort was used in 2 studies assessing brain structural and functional 
correlates of cognitive impairment in PD. Therefore, a more detailed description 
of cognitive battery is provided below. 
Neuropsychological assessment 
In addition to a cognitive screening test, the Montreal Cognitive Assessment 
(MoCA), all subjects underwent a neuropsychological test battery developed to 
assess major cognitive domains affected by PD.  
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Visuospatial function was evaluated using the 15-item version of the Benton’s 
Judgment of Line Orientation Test, which examines the ability of a subject to 
estimate angular relationships between line segments by visually matching 
angled line pairs to 11 numbered radii forming a semi-circle (107).  
Verbal memory was assessed using the Hopkins Verbal Learning Test-Revised 
(HVLT-R) (108), which consists of presenting a list of 12 words over three 
learning trials. With each repetition, subjects are expected to learn additional 
words on the list and increase their performance with each trial. Total immediate 
recall or encoding (sum of trial 1-3) and delayed recall (after 20-25 minutes) 
scores were included in this study.  
Executive functions were evaluated using three semantic fluency tests (names of 
animals, fruits and vegetables, in one minute each), the MoCA subtests of 
phonemic fluency (words that start from the letter “F”, in one minute) and 
alternating trail making (drawing a line, going from a number to a letter, in 
ascending order; score 0-1). 
Attention was assessed by the Letter-Number Sequencing Test (LNST), in which 
a combination of numbers and letters is read to the subject who is then asked to 
recall the numbers, first in ascending order and then the letters in alphabetical 
order. The Symbol Digit Modalities Test (SDMT) was also used to assess 
attention, in which specific numbers had to be paired with geometric figures 
based on a reference key within 90 seconds.  
Diagnosis of MCI 
For the study III, we performed the classification of MCI by an approximation to 
the guidelines of the Movement Disorders Society (MDS) Task Force for the 
level II diagnosis of PD-MCI (109). Since the PPMI study was launched before 
these guidelines had been published, some adjustments had to be made. 
Therefore, the MoCA items were included for the assessment of the five 
cognitive domains: attention and working memory, executive, language, memory 
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and visuospatial. PD patients were classified as PD-MCI if they showed 
impairment in two or more tests or items within the same cognitive domain or in 
two or more domains. Impairment was defined as a score below 2.0 standard 
deviations (SD) for the individual continuous tests or a score below the 
maximum for the ordinal and categorical items. Based on previous 
recommendations made by the MDS Task Force criteria for PDD (110), patients 
were considered to be impaired if they scored below the maximum score on the 
items of MoCA. 
Cognitive Domains  
Three cognitive domains were calculated based on the standardized tests for 
memory, visuospatial and attention/executive functioning. Raw values were 
converted to z-scores using the mean and standard deviation of the healthy 
control group. Domain composite scores were calculated by averaging z-scores 
of the standardized tests in each cognitive domain.  
In the memory domain, three learning trials and the delayed recall of HVLT-R 
were included. The visuospatial domain included the Benton judgment of line 
orientation. The attention/executive domain included the LNST, SDMT, 
semantic fluency and the phonemic fluency test. No corrections were performed 
to adjust the tests scores for age or gender given that the subsequent analyses 
included these variables as nuisances.  
Since the calculated composite scores for cognitive domains were scaled and 
reflected positive cognitive performance (the higher the score, the better 
functioning in a corresponding domain), we defined the “motor” domain by 
inverting and scaling UPDRS-III raw scores in order to achieve the same variable 
scale and direction (higher scores correspond to better motor function) when 
assessing and plotting the results. 
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MRI 
A standardized MRI protocol included acquisition of whole-brain structural and 
functional scans on 3 Tesla Siemens Trio Tim MR system.  
3D T1 structural images were acquired in a sagittal orientation using a MPRAGE 
GRAPPA protocol with Repetition Time (TR) = 2300 ms, Echo Time (TE) = 
2.98 ms, Field of View (FoV) = 256 mm, Flip Angle (FA) = 9° and 1 mm3 
isotropic voxel. 
For each subject, 212 BOLD echo-planar rs-fMRI images (40 slices each, 
ascending direction) were acquired during a 8 min, 29 sec scanning session 
(acquisition parameters: TR = 2400 ms, TE = 25 ms, FoV = 222 mm, FA = 80° 
and 3.3 mm3 isotropic voxels). Subjects were instructed to rest quietly, keeping 
their eyes open and not to fall asleep.  
More details can be found in the MRI technical operations manual at 
http://www.ppmi-info.org/. 
DaTSCAN 
123I-FP-CIT SPECT was performed at the screening visit. Images were acquired 4 
± 0.5 hours after injection of [123I]FP-CIT (111) with a target dose of 185 MBq. 
The radiopharmaceutical was provided as a unit dose and filled to a standard 
volume, which was re-assayed. 
Specific acquisition parameters such as collimation were selected for each center 
at a preceding technical visit.  
Raw projection data were acquired into a 128 x 128 matrix with steps of 3 or 4 
degrees for the total projections. Image preprocessing (reconstruction, 
attenuation correction, spatial normalization) was performed using the Hermes 
software (Medical Solutions, Stockholm, Sweden) at a central SPECT Core lab 
in New Haven (Connecticut, United States). Specific binding ratios were 
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calculated for the left and right caudate nuclei according to specific binding ratio 
= (L/R Caudate)/(Occipital area)-1 and then averaged for further analysis. 
The study presented no risks or harm to participants, confidentiality and 
anonymity were maintained within the legal context of the country, written 
consent was obtained from all subject after the detailed explanation of study 
procedures, approved by Institutional Review Board (Independent Ethics 
Committee). 
 
4.2 Image Preprocessing 
Surface-based framework (Papers I-III) 
Reconstruction of the brain cortex was performed using the Freesurfer software 
(v 5.1) installed on CentOS 5.6 x86-64 workstation. The software is freely 
available for download online (http://surfer.nmr.mgh.harvard.edu). The image 
preprocessing details are described in prior publications (112-116). In short, the 
pipeline includes skull stripping and removal of non-brain soft tissues with a 
hybrid watershed/surface deformation procedure (117), automated Talairach 
transformation, intensity normalization (118), tessellation of the gray matter 
white matter boundary, topology correction (119), and surface deformation to 
optimally place the gray/white and gray/cerebrospinal fluid borders (112, 114). 
After the cortical reconstruction, a number of deformable procedures are 
performed: surface inflation (120), registration to a spherical atlas utilizing 
individual cortical folding patterns to match cortical geometry across subjects 
(116), parcellation of the cerebral cortex into units based on gyral and sulcal 
characteristics (113, 121). This method uses both intensity and continuity 
information from the whole three-dimensional MR volume during segmentation 
and deformation procedures to produce representations of cortical thickness, 
calculated as the closest distance from the gray/white boundary to the gray/CSF 
boundary at each vertex on the tessellated surface (114). The maps are generated 
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using spatial intensity gradients across tissue classes and are not reliant only on 
absolute signal intensity. The maps produced are able to detect submillimeter 
differences between groups. Procedures for the measurement of cortical 
thickness have been validated against histological analysis (122) and manual 
measurements (123, 124). Freesurfer morphometric procedures have been 
demonstrated to show good test-retest reliability across scanner manufacturers 
and across field strengths (125).  
The described surface-based pipeline produced several morphometric modalities: 
cortical thickness (papers I, II, III), Jacobian maps (paper II), sulcal depth (paper 
II).  
At the final step, 327684 normalized measurements acquired for every subject 
were concatenated into large matrices (one for each high-dimensional 
morphometric modality).  
41 volumetric measurements for all subjects (paper II) were corrected for 
intracranial volume (ICV) using linear modeling (removing linear effects of ICV) 
and finally concatenated into a n-by-41 matrix that was used in the subsequent 
analysis. 
Of note, the Freesurfer output for all subjects underwent visual quality control 
and misclassified areas (mainly, regions near cerebellar sinuses and orbitofrontal 
cortex) were corrected manually, blindly to the clinical diagnosis.  
Semi-automated quantification of striatal dopamine transporter binding ratio 
(paper IV) 
The DaTSCAN images were reconstructed using iterative reconstruction 
algorithm as implemented in the Hermes software (Medical Solutions, 
Stockholm, Sweden) at a central SPECT Core lab in New Haven (Connecticut, 
United States). Chang 0 attenuation correction was applied using an empirically 
derived attenuation coefficient, µ, based on measurement at the scanners during 
the preceding technical site visit. Finally, the image volumes were spatially 
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normalized using the mentioned software and a standardized volume of interest 
template was used to determine the spatial location of the right and left caudate 
nucleus and putamen, as well as occipital reference regions. Specific binding 
ratios were calculated for the left and right caudate nucleus and putamen 
according to specific binding ratio=(striatal region)/(occipital)-1.  
Voxel-based framework (paper IV) 
As a first step, a population template was generated from the bias-corrected T1 
structural images using the Diffeomorphic Anatomical Registration Through 
Exponentiated Lie Algebra (DARTEL) algorithm (126) in order to improve 
normalization quality.  
For the fMRI data, two initial echo-planar volumes were automatically removed 
by the scanner software to minimize T1 effects on the T2* echo-planar images, 
and the remaining 210 volumes underwent preprocessing in the SPM8-based 
(http://www.fil.ion.ucl.ac.uk/spm) pipeline implemented in the Data Processing 
Assistant for Resting-State fMRI: Advanced Edition (DPARSFA, version 2.3) 
(127), installed within the MATLAB environment (128).  
Next, functional images underwent the following preprocessing steps: spatial 
realignment and slice-timing correction, co-registration with the high-resolution 
structural scans. Finally, the co-registered BOLD volumes were normalized into 
standardized Montreal Neurological Institute (MNI) space using the DARTEL 
template and resampled to 3 mm3 isotropic voxels. Spurious variance was 
reduced by a voxel-specific head motion correction (129) and by regressing-out 
time-series from the white matter and cerebrospinal fluid. Next, the images were 
smoothed with a 2 mm3 Gaussian kernel, band-pass filtered to eliminate 
biologically non-relevant signals (130, 131) and the resulting low-frequency 
fluctuations were extracted from 90 regions-of-interest defined in the Automated 
Anatomical Labeling (AAL) atlas (132) and were used in the subsequent network 
analysis (133).  
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4.3 Statistical Analysis 
Paper I 
A multivariate analysis of surface-based cortical thickness measurements was 
performed using “spls” (Sparse Partial Least Squares) R-package (version 2.1); 
its methodology has been described elsewhere (134, 135), and the documentation 
is available via the following link: http://cran.r-
project.org/web/packages/spls/spls.pdf. The general principle of this 
methodology is to impose Least Angle Regression (LARS) algorithm for the 
variable selection within the context of partial least squares (135).  
Applying LARS algorithm for the variable selection by penalizing loadings we 
end up with two adjusting parameters: ‘eta’ – the measure of sparsity (varying 
between 0 and 1; when ‘eta’ is 0, regular PLS is used) and ‘K’ – the number of 
latent variables. For the details see (135). 
We chose these parameters within a preliminary specified range (1–5 for ‘K’ and 
0–0.5 with the increment of 0.1 for ‘eta’). We limited our search by 5 latent 
variables (K), since after this point we did not observe significant increase of the 
explained variance percentage, and ‘eta’ value limit was set to 0.5, because, 
according to our previous observations, higher values produce oversmoothed 
models. We applied the described approach for several smoothing kernels of 0, 5, 
10, 15, 20 and 25 FWHM (Full Width at Half Maximum) after removing age-
related effects. 
For each FWHM the best model had been selected based on its mean squared 
error of prediction (MSPE), whereupon the models’ Leave-one–out (LOO) cross-
validated sensitivity and specificity as well as their performance on the 
independent dataset of 27 AD subjects were compared. 
After choosing the best model we plotted its sensitivity and specificity and 
calculated area under the ROC curve (AUC). When reporting sensitivity and 
specificity, we used 0.5 as a cut-off value, which was the middle point between 
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the minimum (0) and maximum (1) likelihoods for Lewy Body Pathology across 
the all models.  
Finally, we mapped the variable coefficients from the best model into the brain 
space in order to define the regions, which were the most relevant for the 
AD/DLB classification. 
Paper II 
Statistical analysis was carried out using the R programming language (R Core 
Team, 2012)(101), version 2.15.1, on R-Cloud built on EBI 64-bit Linux Cluster 
(136). Demographic and clinical features were compared using parametric and 
non-parametric tests as appropriate. Principal component analysis (PCA) from 
the R ‘base’ package was used with visual inspection of PCA score-plot for the 
outlier detection (137). One subject was excluded during this procedure. The 
‘randomForest’ package (138) was used in further analysis. 
The Random Forest algorithm is formally defined as a collection of tree-
structured classifiers: !(!, !!), ! = 1, 2,… ! ,!; where !! are random vectors that 
meet i.i.d. (independent and identically distributed) assumption (139) and each 
tree casts a unit vote for the most popular class at input x (140). For classification 
problems, the forest prediction is the unweighted plurality of class votes 
(majority vote). The algorithm converges with a large enough number of trees. 
For more detailed explanation see (140). 
The R package ‘caret’ (141) was used to implement recursive feature elimination 
(RFE) based on Gini-criterion with 5-fold cross-validation (CV) within the 
context of RF (142). Each of the steps described below were performed for all 
modalities: cortical thickness, sulcal depth, Jacobian maps, non-cortical volumes, 
combined parcellated measurements of cortical thickness and non-cortical 
volumes. First, the measurements with near-zero variance were removed from 
the feature sets and the resulting output underwent stepwise RFE. 10 000 trees 
were used to “grow” the first forest (using full feature set), and afterwards RFE 
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was performed based on feature importance vector (defined in Eq. 2) derived 
from the first forest, by removing lowest-ranked 5% of the features at each step 
(gradually reducing the dimensionality as 100%, 95%, … etc., up to 50%), and 
by the subsequent accuracy comparison with 5-fold CV.  In order to reduce CPU, 
RAM and time usage the forests were trained with 1000 trees (instead of 10 000 
for the first forest) at each step of RFE. After selection of the optimal feature 
subset, mtry-parameter adjustment was also performed using 1000 trees (search 
range ∈ [ !!"#$%&"'! ! ; ! !!"#$%&"' ∗ 2.5], step = !!"#$%&"'! !), and finally the forests 
were retrained with optimal parameters using 10 000 trees. For the parcellated 
data (non-cortical volumes and parcellated thickness), an exhaustive search for 
optimal feature subset and mtry-parameter was performed, “growing” 1000 trees 
at each step with 10-fold CV.  
The following parameters from the final models were reported to characterize 
performance: out-of-bag error [for the term definition see (140)], area under the 
ROC curve (AUC), sensitivity/specificity and overall accuracy on the testing 
datasets of AD, HC and MCI subjects (see “Subsampling”). ROC-curves of the 
best models were compared using DeLong's test for two correlated ROCs, as 
implemented in the ‘pROC’ R-package (143). 
The robustness of each model was also tested with respect to cohort differences 
(using a different cohort of AD and HC subjects from the AddNeuroMed study 
(105).  
Finally, variables of importance were mapped from the best model into the brain 
space in order to identify the regions, which were most relevant for the 
classification. 
The classifiers trained with individual morphometric modality were combined by 
a majority vote and subsequently compared with the best model that 
demonstrated the highest accuracy (the one trained using parcellated thickness 
and volumetric measurements) on the test set. 
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To investigate the effect of different atlases, we selected cortical thickness as a 
measurement type that produced the most accurate models and applied two 
parcellations implemented in the Freesurfer package – Desikan-Killiany (DK) 
and Destrieux (D) atlases – to extract averaged values from the predefined 
regions.  
 
Paper III 
Analyses of clinical and behavioral data were carried out using SPSS 20.0. 
Differences between groups in demographic, socio-demographic, clinical and 
neuropsychological variables were analyzed using Mann-Whitney U tests for 
non-normally distributed data (as indicated by the Kolmogorov-Smirnov test), 
student’s T-test for normally distributed data, and Chi-squared X2 for categorical 
data. Proportions with 95% CI were also calculated.  
The analyses involving neuroimaging data were performed in FreeSurfer. In 
particular, differences in cortical thickness between controls, PD with normal 
cognition (PD-CN) and PD-MCI were examined on the cortical surface maps 
vertex by vertex using a general linear model. Confounding variables such as 
age, gender, education, MRI software version (syngo MR B15 or syngo MR 
B17) and scanner (Siemens Tim Trio or Siemens Verio) were included as 
covariates in these analyses to ensure they did not contribute to any group 
differences. In addition, for the PD-CN and PD-MCI group comparisons, the 
UPDRS III total scores were also included as additional covariates. To assess the 
neuroanatomical substrates of cognitive impairment, correlation analyses 
between cortical surface maps and cognition were also carried out, while 
adjusting for the previous covariates. First, we performed correlations between 
cortical thickness and the z-scores of the three cognitive domains. In addition, 
since by combining tests into domain some specific information might be lost, 
we also correlated cortical thickness with z-scores of the individual continuous 
cognitive tests. In all imaging analyses, cluster-wise correction using Monte 
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Carlo simulation with 10.000 iterations (vertex-wise threshold of p < 0.05) was 
applied in order to control for multiple comparisons.  
 
Paper IV  
Automated meta-analysis  
In order to support our hypotheses and to objectively identify regions that are 
relevant for cognitive functions, an automated search using the meta-analytical 
software Neurosynth (http://neurosynth.org) was undertaken (see Figure M-1). 
This approach utilizes text-mining and machine-learning techniques to perform 
probabilistic mapping between neural and cognitive states (144). In the present 
study, the Python-based version (https://github.com/neurosynth/neurosynth) was 
used. The database was accessed on 24.10.13, searching for the key-words 
“executive” (237 studies), “visuospatial” (n=116) and “memory” (n=1470). 
After the search overlapping patterns were found between cognitive domains. 
They were in line with the regions that have revealed an association with 
cognitive impairment in PD highlighted in the introduction. Thus, the profile of 
visuospatial functions included prefrontal, parietal and occipital regions. The 
“executive” pattern contained prefrontal (with more extended involvement of 
DLPFC), cingulate, superior parietal, temporo-occipital, basal ganglia and 
cerebellar regions. Finally, the “memory” profile, in addition to prefrontal and 
parietal regions, also included hippocampus, temporal areas and basal ganglia.  
Due to the observed overlap, the resulting statistical maps were merged and 
overlaid with the Automated Anatomical Labeling (AAL) atlas in order to have 
an unbiased definition of ROIs associated with cognitive functions for further 
network analysis.  
 
Network Analysis 
The data analysis workflow was developed in order to assess both regional and 
global network-level correlates of presynaptic DAT uptake and cognitive 
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functions. To do this, two metrics were selected: nodal strength (local measure) 
and modularity of a network (global measure). 
The Brain Connectivity Toolbox (BCT, http://www.brain-connectivity-
toolbox.net) (133) was used to compute the described measures. Of note, 
connectivity matrices were neither thresholded nor binarized. Instead we 
employed a strategy that aimed to analyze weighted graphs by taking into 
account both positive and negative weights. 
Next, the analysis proceeded in two directions with the aim of assessing local and 
global network-level correlates of cognitive functioning in PD and the impact of 
nigrostriatal dopaminergic deficiency on these networks. 
All statistical analyses were performed using the R programming language (R 
Core Team, 2012)(101). 
Partial Least Squares Regression (PLSR) was performed to reduce the 
dimensionality of the data, estimating latent components associated with 
composite scores for each domain (executive, memory, visuospatial).  
PLSR is an effective data-driven method that allows high-dimensional 
associations between explanatory and response variables to be reduced into a 
small set of latent variables (LVs) (145). After decomposition, each of the LVs 
represents a distinct pattern of brain–behavior associations.  
The following elements of these components were of particular interest in our 
study: (1) eigenvector (loadings) showing the degree to which a given latent 
variable contributes to the variance within the X-matrix (in our case, brain 
network measures), and (2) a set of scores representing a transform of a 
particular data-point into a latent component’s space (the degree to which a given 
component is “represented” in a particular subject). 
The models were assessed with leave-one-out cross-validation. As a result, 3 
LVs minimizing total Root Mean Squared Error Prediction (RMSEP) for all 3 
domains were selected. Individual LV scores were subsequently correlated with 3 
cognitive domains using motor function, age and sex as nuisance covariates. 
GLM formula: 
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LVN-score ~ (executive domain) + (memory domain) + (visuospatial domain) + 
(motor domain) + (age) + (sex). 
Finally, the scores were correlated with mean caudate DaT binding ratios in order 
to investigate which of them were influenced by nigrostriatal dopamine 
deficiency. The analysis was focused only on the caudate nuclei (without 
putamen), as this striatal structure is well documented to be involved in 
cognition. 
Impact of nigrostriatal deficiency on the modularity of cognitive brain circuitry. 
For the second part, adjacency matrices were constructed using 60 AAL ROIs 
identified during the meta-analysis step. Next, modularity was estimated based 
on both negative and positive weights (as described in Eq. 2a and 2b). 
Finally, an association between network modularity and mean DaT uptake in the 
caudate nuclei was analyzed using linear modeling. 
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5. Results 
Within this project, we studied 1240 patients with Alzheimer’s, Parkinson’s 
disease, Lewy body dementia and mild cognitive impairment, and 325 healthy 
controls, in total (See Table M-1). 
5.1 Paper I 
SPLS Classification: AD vs DLB 
During the search for the optimal model we observed optimal performance for 
FWHM of 20 mm in both cohorts. ‘K’/‘eta’ parameters were set as 2/0.3 for the 
first (Dem- West) cohort and 2/0.4 for the second (Slo) cohort, respectively. 
Sensitivity/specificity/AUC for AD/DLB were 94.4/ 88.89 %/0.978 for the 
DemWest cohort and 88.2/94.1 %/0.969 for the Slo cohort (see Figure 1.1). 
Overall accuracies were 91.64 and 91.15 in the training DemWest and Slo 
datasets, respectively. Additionally, 21 out of 27 probable AD subjects from the 
independent dataset of the DemWest cohort were correctly classified by the 
corresponding model (accuracy = 77.78 %), suggesting appropriate 
generalization. 
In the mixed cohort, ‘K’/‘eta’ parameters were set as 2/0.4. 
sensitivity/specificity/AUC were 82.1/85.7 %/0.948 for the training and 77.8/75 
%/0.731 for testing datasets (overall accuracies were 83.9 and 76.4, respectively). 
As expected, when tested on data from different cohorts (DemWest models on 
Slo data and vice versa) the models failed to produce appropriate accuracy. Thus, 
the DemWest model showed 0.59/0.59/ 0.67 for sensitivity/specificity/AUC on 
the Slo data, and the Slo model demonstrated 0.61/56/0.56 on the DemWest data, 
respectively. 
 
 
 52 
 
Figure 1.1. SPLS model performance. 
 
The graphs are the ROC curves for the classifiers in two cohorts (DemWest, Slo) 
and in the mixed sample, consisted of the equivalently combined training dataset 
(26/ 26 AD and DLB patients) and of the independent dataset (remaining 36/9 
AD/DLB cases). Leave-one-out cross validation performance is plotted for each 
model. For the mixed sample, classifier performance on the independent dataset 
is also provided. FWHM full width at half maximum (smoothing kernel), VN 
number of the selected features (vertices), opt.K/opt.eta optimal ‘K’ (number of 
latent components) and ‘eta’ (sparsity) parameters, MSPE mean squared 
prediction error, AUC area under the ROC curve. 
Regions of relevance for AD/DLB classification 
Mapping the coefficients into the brain space revealed several regions, which 
appeared to be the most relevant for the classification. The pattern of difference 
was similar in all cohorts (Figure 1.2). Cortical thinning, which increased the 
chances for the subject to be classified as an AD patient, was observed bilaterally 
in anterior parahippocampal region and temporal pole (the most relevant areas), 
subcallosal (subgenual cingulate) and occipital regions. 
 
 53 
Figure 1.2. Regions of relevance for AD/DLB classification. 
 
The figure shows regions of relevance for AD/DLB classification from three 
models obtained in DemWest, Slo and mixed cohorts. The last sample consisted 
of the equivalently combined training dataset (26 AD and 26 DLB patients) and 
of the independent dataset (remaining 36/9 AD/ DLB cases). Red spectrum 
reflects pattern of cortical thinning that increased chances for the subject to be 
classified as an AD patient. Green spectrum is the regions of importance for 
DLB. 
Cortical thinning relevant for DLB was observed bilaterally in the cingulate 
region (affecting middle and posterior parts on the right side and middle on the 
left), superior temporo-occipital areas, and lateral orbitofrontal cortex. 
In the DemWest and in the mixed sample, AD-associated patterns also included 
changes in the parietal region, whereas DLB-supportive thinning was 
additionally found in insular area. This was not observed in the Slo cohort. 
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5.2 Paper II 
AD/HC Classification  
Three models had competing performances on the testing set (Figure 2.1). The 
model trained using high-dimensional thickness measurements demonstrated 
AD-detection sensitivity/specificity of 88.6%/90.7%, its AUC (95% C.I.) was 
0.93 (0.9-0.96); while the model trained using volumetric measurements resulted 
in sensitivity/specificity = 82.9%/86.7%, AUC = 0.91 (0.88-0.95); and using 
parcellated measurements of cortical thickness and subcortical structures resulted 
in sensitivity/specificity = 88.6%/92.0%, AUC = 0.94 (0.91-0.96).  
Figure 2.1. ROC curves: Morphometric Modalities (AD/HC) 
 
The figure illustrates ROC-curves of the models trained with different 
morphometric input. Three inputs demonstrate competing performances: high-
dimensional (HD) cortical thickness, volumetric data and combined parcellated 
measurements. 
AD/HC – Alzheimer’s Disease / Healthy Controls 
The best ability to predict MCI-to-AD conversion based on imaging data only 
was observed for the model in which all RF ensembles were combined by a 
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majority vote, and was achieved at 76.6% in overall MCI-to-AD conversion 
detection sensitivity, 2 years before actual dementia onset (averaged value for 
6th-, 12th-, 18th- and 24th-month converters) with a specificity of 75.0%. 
Adding ApoE genotype and demographics (age, sex, education) as additional 
predictors into our best AD/HC model, trained using combined cortical thickness 
and non-cortical volumetric measurements, did not improve AD/HC 
classification accuracy (sensitivity/specificity/OA = 90.7%/82.9%/86.7%). 
However, its accuracy for MCI-to-AD conversion was significantly higher 
compared to other models with maximum sensitivity/specificity/OA values of 
83.3%/81.3%/82.3%. Averaged sensitivity for the first two-year converters was 
79.2%. 
Robustness in different cohorts 
Testing the ADNI models on AddNeuroMed data revealed good generalizability 
of the classifiers. The best stability (both for AD detection and prediction) was 
found for the models trained with high-dimensional measures of cortical 
thickness and parcellated thickness with volumetric measures. Combined models 
trained using both imaging and non-imaging data demonstrated absence of 
accuracy drop (see Table 2.1). 
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Table 2.1. Classifiers’ performance in the same (ADNI) and separate 
(AddNeuroMed) cohorts. 
Models 
AD: Sens/Spec (OA) MCI-converter 1yr sensitivity* 
Same cohort 
(ADNI) 
Separate cohort 
(AddNeuroMed) 
Same cohort 
(ADNI) 
Separate cohort 
(AddNeuroMed) 
Thickness 
88.6%/90.7% 
(89.62%) 
87%/78% (82.5%) 79.0% 76.2% 
Sulcal Depth 
80.0%/74.7% 
(77.3%) 
Failed 74.4% Failed 
Jacobian 
77.1%/81.3% 
(79.2%) 
78.5%/72% 
(75.25%) 
65.4% 57.1% 
Volumes 
82.9%/86.7% 
(84.7%) 
70.1%/89% 
(79.5%) 
75.7% 57.1% 
Thickness + 
volumes (parc) 
88.6%/92.0% 
(90.3%) 
83.2%/89% 
(86.1%) 
79.0% 71.4% 
Morphometry 
+ApoE 
+demographics 
90.7%/82.9% 
(86.7%) 
84.2%/88.3% 
(86.25%) 
78.0% 79% 
The classifiers were trained on the subset from the ADNI dataset and then 
validated on testing sets from both ADNI (same) and AddNeuroMed (separate) 
cohorts. 
Sens/Spec (OA) – Sensitivity/Specificity (Overall Accuracy); 
* – for the AddNeuroMed cohort, definition of the MCI-to-AD converters 
subgroup (n=21) was defined based on 1-year follow-up. 
NB: We did not compare accuracy to detect MCI non-converters due to only 1-
year follow-up available for the AddNeuroMed cohort 
 
Regions of relevance  
As expected, the observed pattern of feature relevance was typical for AD and 
similar in models trained using high-dimensional and parcellated input (Figures 
2.2 and 2.3. It included atrophy in temporal areas (with more extensive changes 
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in entorhinal cortex, hippocampus, amygdala), lateral ventricular size differences 
and parietal cortical abnormalities. 
Figure 2.2. Cortical pattern of relevance for Alzheimer's Disease detection: high-
dimensional morphometric data. 
 
The figure illustrates regions, which were the most relevant for Alzheimer’s 
disease detection based on the mean decrease of the Gini index. In all three high-
dimensional modalities, the pattern was AD-specific and included changes 
predominantly in temporal lobes (with maximum relevance of entorhinal region). 
 
 
 
 
 
 
 
 
 58 
Figure 2.3. Pattern of relevance for Alzheimer's Disease detection: parcellated 
morphometric data (cortical thickness [DK-atlas] + non-cortical volumes). 
 
ctx – cortex; Inf. – inferior; Mid. – middle; Sup. – superior; 
STS – superior temporal sulcus. 
The figure illustrates regions, which were the most relevant for Alzheimer’s 
Disease detection based on the mean decrease of the Gini index. Likewise in the 
high-dimensional input, the pattern-of-relevance is AD-specific. 
 
5.3 Paper III 
Cortical thickness in PD with and without MCI 
Mass-univariate analysis revealed cortical thinning in the right inferior temporal 
gyrus in PD-CN patients compared to healthy controls (Figure 3.1). 
Comparison of PD-MCI with healthy controls revealed bilateral atrophy in this 
area, with more prominent thinning in the left hemisphere. Apart from this, PD-
MCI patients demonstrated changes in the left superior parietal cortex, 
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precuneus, lateral occipital, temporal, anterior cingulate and superior frontal 
areas (Figure 3.1). 
Compared to PD-CN, PD-MCI patients demonstrated greater thinning in the left 
precuneus (Figure 3.1).  
Figure 3.1. Mass-univariate comparison of cortical thickness between A) 
controls and cognitively normal PD patients (PD-CN), B) controls and PD 
patients with MCI (PD-MCI) and C) PD-CN and PD-MCI, following the 
modified PD-MCI-MDS criteria and the PD-MCI-Domains criteria. 
 
The color scale bar shows the logarithmic scale of p-values (-log10). Rh, Right 
hemisphere; Lh, Left hemisphere. 
 
 
Cortical thickness and cognitive performance 
Results of the analysis of associations between cortical thickness and cognitive 
domains composite scores are shown in Figure 3.2. 
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Visuospatial performance was associated with superior parietal thickness 
bilaterally with more extended associations in the right hemisphere (cluster also 
included the right superior frontal gyrus and precuneus) 
The executive domain scores revealed associations with cortical thickness in the 
superior frontal, precentral, temporal and parietal regions (Figure 3.2).  
Composite scores of the memory domain did not reveal significant associations 
with thickness in any cortical area. 
Figure 3.2. Mass-univariate GLM analysis of associations between cortical 
thickness and composite scores in the Visuospatial (A) and Executive (B) 
cognitive domains in PD patients. 
 
The color scale bar shows the logarithmic scale of p-values (-log10). Rh –  Right 
hemisphere; Lh – Left hemisphere.
5.4 Paper IV 
In this study, PLS was used for dimensionality reduction. Each PLS LV score 
represents one brain-behavior covariance pattern. 
 
Nodal Strength 
The first PLS LV represented global effects. Its higher scores were associated with 
higher strength of all 90 nodes with largest effects on motor, prefrontal cortices and 
striatum. On a behavioral level, this component was positively associated with motor 
function (see Figure 4.1). 
The second LV was associated with higher degree of posterior (supramarginal, 
superior parietal, posterior cingulate, occipital regions) and striatal nodes, and lower 
prefronto-limbic (orbitofrontal, anterior cingulate, parahippocampal, temporopolar 
regions) nodal strength (except for operculo-triangular, middle frontal areas and left 
hippocampus, which demonstrated positive associations). Behaviorally, this 
component displayed a negative association with memory function, that is to say that 
better memory performance was associated with reversed component pattern, 
favoring the involvement of prefronto-limbic nodes (see Figure 4.1).  
The third LV, in turn, favored cortical-subcortical segregation with positive 
associations found in dorsal cortical nodes (dorsolateral prefrontal, frontal and 
parietal areas) and negative in subcortical structures (hippocampi, striatum, globus 
pallidus), primary visual, middle temporal and paralimbic (ventral prefrontal) areas. 
Higher scores of this component were associated with better executive performance 
(see Figure 4.1) 
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Figure 4.1. Associations between component scores and cognitive functions. 
 
 
A: Between-component correlation plot. Positive association (r=0.5) was found 
between latent variables (LVs) I and III. 
B: Associations between LV scores extracted from the nodal strength data and 
performance in 3 cognitive (executive, memory, visuospatial) and motor domains. On 
the right-hand side of the graph, corresponding loading maps are depicted in brain 
space, reflecting the relevance of the nodes (spheres) for a particular LV, the 
magnitude of which is represented by nodal size. Positive loading values are depicted 
as red spheres, whereas negative ones are shown in blue. 
* - p<0.05 
** - p<0.01 
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Latent Variable scores and caudate DaT uptake 
Analysis of the effects of nigrostriatal dopaminergic deficiency on the LVs estimated 
from the nodal strength revealed significant positive associations of mean caudate 
SBR ratios with I and III LV-scores (Figure 4.2). 
This means that higher caudate DaT binding is associated with global increase of 
nodal strength and segregation toward more active dorsal cortical processing when 
the subject is at rest. 
 
Figure 4.2. Associations between component scores and mean caudate DaT binding. 
 
Associations of latent variable (LV) scores extracted from the nodal strength data 
with nigrostriatal dopaminergic function measured by 123I-FP-CIT SPECT (mean 
caudate SBR ratios). 
Positive associations (* - p<0.05) were found for the Ist (“global/motor”) and IIIrd  
(“executive”) LVs.  
Corresponding loading maps are depicted in brain space, reflecting the relevance of 
the nodes (spheres) for a particular LV, the magnitude of which is represented by 
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nodal size. Positive loading values are depicted as red spheres, whereas negative 
ones are shown in blue. 
 
Modularity of the cognitive circuitry and caudate DaT uptake 
The analysis revealed negative effects of the preserved dopaminergic function on 
modularity of the cognitive circuit (T = -3.6, 17 DOF, p=0.002), suggesting greater 
integration among regions within this network (see Figure 4.3) 
 
Figure 4.3. Caudate DaT uptake and modularity of the cognitive circuitry at rest. 
 
The figure shows significant (p<0.01) negative association between modularity of the 
cognitive circuitry (identified with automated meta-analysis) and nigrostriatal dopaminergic 
function measured by 123I-FP-CIT SPECT (mean caudate SBR ratios). 
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6. Discussion 
In this thesis we found that cognitive impairment in the elderly has different brain 
profiles depending on the predominant neurodegenerative pathology and affected 
cognitive functions.  
Our work is one of the first to demonstrate that with use of pattern recognition 
techniques applied for MRI data, DLB can be successfully differentiated from AD. 
This finding was replicated in two independent cohorts (paper I). 
The results also suggest that with use of automated computer-aided tools and 
advanced image processing techniques, Alzheimer’s disease can be robustly 
identified and predicted two years before the actual dementia onset.  
Previous studies have successfully employed pattern recognition techniques to 
classify MRI images from different cohorts only within the combined sets (146).  In 
this thesis we showed that employing our methodology, it is possible to produce 
classifiers not only with high accuracy, but also with good between-cohort robustness 
when imaging protocols are carefully aligned (paper II). 
We also demonstrated that the accuracy to predict MCI-to-AD conversion (but not 
AD detection) could be further improved by adding other biomarkers (such as ApoE-
genotype) and demographic data. This effect was demonstrated in two completely 
independent cohorts from North America and Europe (paper II). Further 
improvement in MCI-to-AD prediction accuracy can potentially be achieved by 
adding more imaging and non-imaging (i.e., cerebrospinal fluid levels of amyloid-
beta, p-tau and t-tau (147)) biomarker modalities and/or by using better image post-
processing protocols.  
To the best of our knowledge, our work is also the first to investigate the impact of 
different parcellation schemes and dimensionality of the imaging features on machine 
learning modelling accuracy, computation/memory and time costs.  In the present 
work (paper II), more disease-specific parcellation scheme (Destrieux’s) produced 
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more accurate models (paper II). Measurement-specific parcellation schemes may 
also be useful for further accuracy improvement. 
Using the largest cohort (to date), our work demonstrated that MCI in PD is 
associated with temporo-parietal and superior frontal thinning and that memory, 
visuospatial and executive cognitive performances are related to temporo-parietal and 
superior frontal thinning (paper III). In contrast to previous studies suggesting that 
PD without cognitive impairment is not associated with brain atrophy (148, 149), we 
also found that temporal thinning is present even in PD patients that do not meet 
criteria for MCI.  
On a large-scale network level, better executive performance in PD is associated with 
increased dorsal fronto-parietal cortical processing and inhibited subcortical and 
primary sensory involvement when the subject is at resting state. This pattern is 
positively influenced by the relative preservation of nigrostriatal dopaminergic 
function (paper IV). In general, higher DaT binding values had integrative effects on 
the brain (global increase of nodal strength). These findings are in line with previous 
functional studies employing different methods that revealed abnormally enhanced 
fronto-subcortical connectivity in PD (87, 150-153) 
Influence of nigrostriatal deficiency on brain dynamics underlying PD-related 
cognitive impairment was also confirmed using global graph theoretical metrics, 
when higher DaT SBR ratios (relative preservation of dopaminergic function) were 
associated with lower modularity of cognitive circuitry defined with automated meta-
analysis. This is also in line with previous fMRI and magnetoencephalography 
studies that indicated globally impaired network-level processing in PD (154-156). 
The basal ganglia are known to be crucial for sustaining the balance between 
facilitation and suppression of movements (157). Under certain assumptions, 
executive functions can be considered as the “movement of thoughts” within this 
context. According to a widely accepted notion of cognitive cortico-strio-thalamo-
cortical loops, DLPFC circuit mediates set-shifting, complex problem-solving, 
retrieval abilities, organizational strategies, concept-formation, working memory 
 67 
(158) and other executive functions known to be affected in PD. The nigrostriatal 
dopamine system therefore may not only allow effective execution/termination of 
motor activity, but may also assist in smooth switching between cognitive patterns, 
controlling mutual inhibition and/or facilitation of fronto-subcortical circuits. This is 
also supported by computational models of the basal ganglia that highlight their 
routing role in various cognitive functions, particularly for action-selection (159). 
Several limitations of our work have to be acknowledged. Nearly all patients were 
diagnosed clinically, and thus there is a risk for misclassification. This is especially 
relevant for study I, since DLB and AD can be difficult to differentiate, and mixed 
Alzheimer’s and Lewy body pathology may be present in both AD and DLB groups. 
However, preliminary post-mortem pathological diagnosis is now available for 21 
patients from the DemWest study, and all cases with a clinical diagnosis of probable 
DLB had cortical or limbic Lewy bodies. In addition, the use of DaTSCAN to 
confirm the diagnoses of DLB and PD (papers I, III, IV) is a strength that partially 
overcomes this issue. Another limitation is relatively small sample sizes in the studies 
I and IV, which may influence feature selection and modeling accuracy. However, 
the results from study I were replicated in two independent cohorts, and the results of 
the study IV had high statistical significance and were replicated with two 
independent approaches using both local (nodal strength) and global metrics 
(modularity of the cognitive circuitry, defined with meta-analysis). In study III, there 
is also a potential bias of including “super-normal” controls with MoCA scores > 26, 
which may artificially increase the difference between PD and control subjects. For 
the PPMI-based studies (III and IV), there may also be a selection bias due to the fact 
that the subjects were recruited from highly specialized research centers and might 
not be representative of a population-based sample. From a methodological 
standpoint, in study IV, the resting state setting hampers direct interpretation of the 
findings regarding to the role of brain circuits in the performance of cognitive tasks. 
Active cognitive processing is associated with patterns of brain dynamics that are 
different from the ones occurring at rest. These patterns may have different 
associations with altered dopaminergic function in PD. Another limitation of study IV 
pertains to the specificity of nigrostriatal dopaminergic deficiency measured by 123I-
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FP-CIT SPECT, which might also reflect indirect effects of neurodegeneration of 
dopaminergic neurons within other pathways (because the severity of dopaminergic 
deficits may correlate across different systems). Therefore, the results of the study IV 
should be interpreted with caution. Finally, it is necessary to note that all the cohorts 
(except for the Slovenian sample) are drawn from the multicenter studies (DemWest, 
ADNI, AddNeuroMed, PPMI). Within this context, harmonization of clinical and 
imaging protocols is especially crucial and may represent an issue if not carefully 
completed. For these studies, cross-center harmonization and reliability assessment 
steps have been performed using artificial and human phantom scans. Necessity of 
the harmonization has specifically been demonstrated in the study I, when the model 
trained on the data from one cohort did not produce appropriate performance on the 
imaging data acquired without MRI protocol harmonization. However, the model was 
still effective when trained on the mixed data from non-harmonized cohorts.  
 
Computer-aided framework for the diagnosis of cognitive impairment in clinical 
practice 
Our findings provide a good support for further diagnostic clinical trials of image-
based computer-aided models for diagnosis and monitoring of cognitive impairment, 
particularly for Alzheimer’s disease, and suggest that there is a potential of such an 
implementation for the diagnosis of cognitive impairment associated with PD. 
Computerized medical decision-support systems is a rapidly developing field with a 
very strong potential to be used in clinical practice. The results of the present thesis 
deepen our understanding of brain mechanisms underlying cognitive impairment in 
the elderly and suggest good implementation feasibility of CAD systems.  
However, it is important to note that CAD systems should not be considered as a 
substitute for a clinician or any other medical specialist. Instead, such a framework 
implies the use of predictions from computer models as a second opinion that can be 
taken into account or rejected depending on the clinical context.  
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In practice, there are many levels at which CAD systems may be beneficial and can 
be incorporated within the clinical setting (Figure D-1). 
 
Figure D-1. Application of CAD in geriatric practice: general scheme. 
 
Thus, for example, making a decision on whether a patient with subjective cognitive 
impairment should be further evaluated, treated or carefully monitored can be 
substantially augmented with use of CAD. Likewise, such a framework can be used 
to aid differential diagnosis and prediction of further cognitive decline among 
patients with early stages of neurodegenerative disease, and finally, to enroll patients 
at early stages of the diseases to the clinical trials in order to make such interventions 
most effective and beneficial for the patients. 
Nevertheless, it is important to acknowledge that computer-aided medical decision 
support systems are much more than just optimized pipelines, producing reliable and 
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accurate models. Instead, such an implementation requires a user-friendly interface 
easily accessible for a clinician after the specific training is completed. 
Clinicians do not necessarily need to participate in the image preprocessing at any 
stage except for probably general image quality control step. An ideal CAD system of 
this kind would be software with “point-and-click” interface that would take DICOM 
images as an input and produce the required measures and predictions as an output.   
Incorporating this is not an easy task to accomplish for several reasons. First of all, 
image-processing packages are being constantly updated improving quality and 
efficiency of the data preparation step. This, in turn, influences prediction accuracy of 
the models and not always towards its improvement. Pattern recognition algorithms 
and their implementations are also being optimized in the newest version of the 
toolboxes. All of the above requires flexible and modifiable implementation, as well 
as coordinated work of several IT and medical specialists. On the other hand, there is 
a well-known tradeoff between functionality/capability on the one side and 
complexity/cost on the other. Therefore, every update of the software should be 
standalone and non-modifiable for the clinical users. 
Another important issue pertains to the clinical setting itself, within which 
information about patients and clinical details including the diagnosis itself can be 
changed after a while. Within the context of continuous image data and clinical 
information flow it would be beneficial to incorporate so-called “online” machine 
learning setting, where the model gradually "learns" using one instance at a time 
(instead of traditional "offline" or “batch” learning framework, where the whole 
training set is available to the algorithm at the beginning and therefore does not allow 
any modifications of the models after the training has been completed). 
This framework also provides valid estimations of the prediction confidence under a 
general i.i.d. assumption (independent and identically distributed) (160-162).  
Since this approach can be applied to an individual patient and gives reliable 
estimations of possible diagnoses, it has strong potential to be used in clinical practice 
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and, to our opinion, would be the best candidate for diagnostic trials employing 
computer-aided medical decision-support systems. 
There are also many important organizational issues pertaining to the implementation 
of CAD system in clinical practice, which were beyond the scope of the thesis, such 
as incentives for clinicians and practicalities related to data transfer and patients’ 
confidentiality. These issues are relevant for any IT innovations in medicine and can 
be effectively addressed as well. 
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7. Conclusions 
Cognitive impairment in the elderly has different brain profiles depending on the 
predominant neurodegenerative pathology and cognitive functions affected. With the 
use of automated computer-aided tools and advanced image processing techniques, 
Alzheimer’s disease can be robustly identified, predicted two years before the actual 
dementia onset and differentiated from dementia with Lewy bodies. After certain 
modifications and adaptations for clinicians, the models can be successfully 
incorporated into medical decision-support systems and be evaluated in subsequent 
diagnostic clinical trials. 
The identified brain structural and functional profile associated with Parkinson’s-
related cognitive impairment is also robust and, holding strong diagnostic potential, 
must be detectable using computer-aided systems of similar design, the development 
of which is the matter of our future research. The development and future elaboration 
of clinically realistic computer-aided systems for the diagnosis of neurodegenerative 
diseases is an important topic for future research. 
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